Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseases

Reuters2026/08/14 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alumis highlighted Phase 3 psoriasis efficacy for envudeucitinib, citing Week 24 PASI 100 of 41% in ONWARD1, 39.5% in ONWARD2.
Long-term extension ONWARD3 showed 48-week PASI 90 of 75% and PASI 100 of 54% in 773 patients.
NDA filing for envudeucitinib in plaque psoriasis targeted for 4Q 2026.
Potentially pivotal Phase 2b systemic lupus erythematosus topline data expected in 3Q 2026.
A-005 Phase 2 biomarker trial initiation in Parkinson’s disease planned for 1H 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alumis publishes corporate deck on next-generation TYK2 inhibitors for immune-mediated diseases

You may also like

Crypto prices